This application is to establish a U54 Medication Development Center of Excellence (MDCE). The proposed MDCE will be integrated within the umbrella of the Penn/VA Center for Studies of Addiction (CSA) and benefits greatly from that integration, permitting access to infrastructure and resources not generally available outside of a large research center. The MDCE has priority access to important resources: 1) the Berrettini genetics lab 2) the Center biostatistician; 3) a web-based Data Management Unit; and, 4) state-of the-art Brain Imaging. Our theme is the identification and comprehensive screening of innovative medications for the treatment of Cocaine Use Disorder (CUD). Our MDCE proposes to emphasize novel medications such as BP1.4979, a dopamine D3 partial agonist, the GABA B agonist, long acting baclofen and clavulanic acid (CLAV). In addition, we will improve our ability to identify efficacious new medications by identifying characteristics of CUD patients that may increase their likelihood of responding positively to a particular medication and by streamlining the identification of medication responders in clinical trials. The Administrative Core will coordinate and integrate a Human Laboratory and Genetics Pilot Program, an Education Core, a Biostatistics and Data Management Core and three research projects. The Human Laboratory and Genetics Pilot Program will employ neurobehavioral tasks that may aid in the detection of medication responders early in treatment and will explore pharmacogenetic interactions that could explain and potentially capitalize on heterogeneity in medication response. The research projects are arranged to allow for novel medications to be studied from safety through preliminary efficacy. In Project 1, we will administer cocaine to volunteers while receiving either BPI .4979 or CLAV to test for potential toxic interactions with cocaine, providing safety and preliminary efficacy data for these compounds. Project 2 will provide neurobehavioral and neuroimaging data to determine whether medications selected for study effectively engage the appropriate brain targets at the dosages proposed for study. Project 3 proposes to evaluate promising novel compounds in 12-week, placebo-controlled trials. By providing comprehensive screening of candidate medications and sequentially testing them, as described, we expect to rapidly identify effective medications that justify investment in the next level of development, multi-site efficacy trials.

Public Health Relevance

Cocaine Use Disorder (CUD) is a significant public health problem responsible for substantial medical, psychiatric, and economic costs. There are currently no medications approved for the treatment of CUD. The development of an effective pharmacotherapy for CUD has the potential to significantly impact the public health by addressing the needs of a sizable treatment population.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Walton, Kevin
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Gawrysiak, Michael J; Jagannathan, Kanchana; Regier, Paul et al. (2017) Unseen scars: Cocaine patients with prior trauma evidence heightened resting state functional connectivity (RSFC) between the amygdala and limbic-striatal regions. Drug Alcohol Depend 180:363-370
Li, Hongming; Satterthwaite, Theodore D; Fan, Yong (2017) Large-scale sparse functional networks from resting state fMRI. Neuroimage 156:1-13
Li, Peng; Jing, Ri-Xing; Zhao, Rong-Jiang et al. (2017) Electroconvulsive therapy-induced brain functional connectivity predicts therapeutic efficacy in patients with schizophrenia: a multivariate pattern recognition study. NPJ Schizophr 3:21
Regier, Paul S; Monge, Zachary A; Franklin, Teresa R et al. (2017) Emotional, physical and sexual abuse are associated with a heightened limbic response to cocaine cues. Addict Biol 22:1768-1777
Crist, R C; Doyle, G A; Kampman, K M et al. (2016) A delta-opioid receptor genetic variant is associated with abstinence prior to and during cocaine dependence treatment. Drug Alcohol Depend 166:268-71
Wetherill, Reagan R; Hager, Nathan; Jagannathan, Kanchana et al. (2016) Early Versus Late Onset of Cannabis Use: Differences in Striatal Response to Cannabis Cues. Cannabis Cannabinoid Res 1:229-233
Wetherill, Reagan R; Hager, Nathan; Guthier, Emily et al. (2016) Gram Years: A Method to Standardize and Quantify Lifetime Cannabis Consumption. Cannabis Cannabinoid Res 1:216-217
Wang, Ze; Suh, Jesse; Li, Zhengjun et al. (2015) A hyper-connected but less efficient small-world network in the substance-dependent brain. Drug Alcohol Depend 152:102-8
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Winhusen, Theresa M; Kropp, Frankie; Lindblad, Robert et al. (2014) Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. J Clin Psychiatry 75:757-64

Showing the most recent 10 out of 16 publications